Antiphospholipid syndrome (APS) is an autoimmune hypercoagulable disorder that has been shown to cause a large number of cardiac and neurological manifestations. Two recent studies have demonstrated abnormalities in cardiovascular autonomic function testing in APS patients without other cardiovascular or autoimmune disease. However, an association between autonomic disorders such as postural tachycardia syndrome and APS has not previously been described.
Methods and results
Data were obtained by retrospective chart review. We identified 15 patients who have been diagnosed with APS and an autonomic disorder. The median age of the patients at the time of data analysis was 39 years. The autonomic disorders seen in these patients included postural tachycardia syndrome, neurocardiogenic syncope and orthostatic hypotension. The majority of patients (14/15) were female and the majority (14/15) had non-thrombotic neurological manifestations of APS, most commonly migraine, memory loss and balance disorder. Many also had livedo reticularis (11/15) and Raynaud’s phenomenon (nine of 15). In some patients, the autonomic manifestations improved with anticoagulation and/or anti-platelet therapy; in others they did not. Two patients with postural tachycardia syndrome who failed to improve with the usual treatment of APS have been treated with intravenous immunoglobulin with significant improvement in their autonomic symptoms.
Conclusion
We believe that autonomic disorders in APS may represent an important clinical association with significant implications for treatment.
KoniariISiminelakisSNBaikoussisNGPapadopoulosGGoudevenosJApostolakisE. Antiphospholipid syndrome; its implication in cardiovascular diseases: A review. J Cardiothorac Surg2010; 5: 101–111.
2.
TenediosFErkanKLockshinMD. Cardiac involvement in the antiphospholipid syndrome. Lupus2005; 14: 691–696.
3.
SilbigerJJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr2009; 22: 1100–1108.
4.
ScantleburyDCNkomoVTEnriquez-SaranoM. Antiphospholipid syndrome and recurrent thrombotic valve disease. J Am Coll Cardiol2013; 61: e177–e177.
5.
NairSKhamashtaMAHughesGRV. Syndrome X and Hughes syndrome. Lupus2002; 11: 332–332.
6.
ChristodoulouCSangleSD’CruzDP. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology (Oxford)2007; 46: 907–910.
7.
TektonidouMG. Renal Involvement in the antiphospholipid syndrome (APS)—APS nephropathy. Clin Rev Allergy Immunol2009; 36: 131–140.
8.
SangleSD’CruzDPKhamashtaMAHughesGRV. Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures. Ann Rheum Dis2004; 63: 1241–1243.
9.
UthmanIGodeauBTaherAKhamasthaM. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev2008; 22: 187–194.
10.
FrancèsCNiangSLaffitteEPelletierFICostedoatNPietteJC. Dermatologic manifestations of the antiphospholipid syndrome: Two hundred consecutive cases. Arthritis Rheum2005; 52: 1785–1793.
11.
SannaGD’CruzDCuadradoMJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am2006; 32: 465–490.
12.
HughesGRV. Connective tissue disease and the skin. Clin Exp Dermatol1984; 9: 534–544.
13.
BiloraFBiasioloMZancanA. Autonomic dysfunction and primary antiphospholipid syndrome: A frequent and frightening correlation?Int J Gen Med2012; 5: 339–343.
14.
GarciaCPerandiniLSeguroL. Impaired aerobic exercise capacity and cardiac autonomic control in primary antiphospholipid syndrome. Lupus2013; 22: 928–931.
15.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
FreemanRWielingWAxelrodFB. Consensus statement of the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci2011; 161: 46–48.
18.
TsutsumiAHoritaTOhmuroJ. Reflex sympathetic dystrophy in a patient with the antiphospholipid syndrome. Lupus1999; 8: 471–473.
HughesGRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ1983; 287: 1088–1089.
21.
HughesGRV. Heparin, antiphospholipid antibodies and the brain. Lupus2012; 21: 1039–1040.
22.
HarperBEWillsRPierangeliSS. Pathophysiological mechanisms in antiphospholipid syndrome. Int J Clin Rheumtol2011; 6: 157–171.
23.
ShoenfeldYNahumAKorczynAD. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus2003; 12: 436–442.
24.
Benrud-LarsonLMDewarMSSandroniPRummansTAHaythornthwaiteJALowPA. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc2002; 77: 531–537.
25.
ThiebenMJSandroniPSlettenDM. Postural orthostatic tachycardia syndrome: The Mayo clinic experience. Mayo Clin Proc2007; 82: 308–313.
26.
KanjwalKKarabinBKanjwalYGrubbBP. Autonomic dysfunction presenting as postural tachycardia syndrome following traumatic brain injury. Cardiol J2010; 17: 482–487.
27.
BlitshteynS. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol2014; 21: 135–139.
KanjwalKSaeedBKarabinBKanjwalYGrubbB. Comparative clinical profile of postural orthostatic tachycardia patients with and without joint hypermobility syndrome. Indian Pacing Electrophysiol J2010; 10: 173–178.
HonczarenkoKBudzianowskaAOstanekL. Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurol Neurochir Pol2008; 42: 513–517.
WangXLChaiQCharlesworthMC. Autoimmunoreactive IgGs from patients with postural tachycardia syndrome. Proteomics Clin Appl2012; 6: 615–625.
35.
LiHKemDCReimS. Agonistic autoantibodies as vasodilators in orthostatic hypotension: A new mechanism. Hypertension2012; 59: 402–408.
36.
IodiceVKimpinskiKVerninoSSandroniPFealeyRDLowPA. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology2009; 72: 2002–2008.
37.
CuadradoMJKhamashtaMAD’CruzDHughesGR. Migraine in Hughes syndrome—heparin as a therapeutic trial?QJM2001; 94: 114–115.
38.
OaklanderALKleinMM. Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. Pediatrics2012; 131: 2597–2607.
39.
NovakPWilliamsARavinPZurkiyaOAbduljalilANovakV. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol2012; 12: 131–131.
40.
ShererYLevyYShoenfeldY. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology1999; 39: 421–426.
41.
SciasciaSLopez-PedreraCRoccatelloDCuadradoMJ. Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol2012; 26: 535–541.
42.
ErkanDVegaJRamónGKozoraELockshinMD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum2013; 65: 464–471.
